Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $1.8 million.

  • Dna X's Other Non-Current Liabilities rose 1239.16% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 1239.16%. This contributed to the annual value of $1.7 million for FY2024, which is 1119.11% up from last year.
  • Latest data reveals that Dna X reported Other Non-Current Liabilities of $1.8 million as of Q3 2025, which was up 1239.16% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Other Non-Current Liabilities registered a high of $1.8 million during Q3 2025, and its lowest value of $1.3 million during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $1.5 million (2023), whereas its average is $1.5 million.
  • In the last 5 years, Dna X's Other Non-Current Liabilities tumbled by 4070.09% in 2021 and then surged by 1612.48% in 2025.
  • Dna X's Other Non-Current Liabilities (Quarter) stood at $1.4 million in 2021, then grew by 1.42% to $1.4 million in 2022, then rose by 6.93% to $1.5 million in 2023, then grew by 11.19% to $1.7 million in 2024, then grew by 6.77% to $1.8 million in 2025.
  • Its Other Non-Current Liabilities was $1.8 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.8 million in Q1 2025.